In the containment of a potential epidemic, accurate diagnostics are critical for the foundation of the epidemiologic studies used by authorities to decide on the best course of action. A failed QC process or false negative result for the COVID-19 virus does not necessarily indicate that the analytical technology was inaccurate. Advanced analysis cannot compensate for a sample that was poorly extracted and incompletely prepared. For example, both real time RT-PCR for rapid detection and/or high-throughput sequencing for metagenomic studies require effective pre-analytical sample preparation. Jim Laugharn, Founder and CEO of Covaris commented, "Robust and efficient sample preparation is the key to reducing false negative results when processing difficult input biological samples such as swab specimens. Our goal is to standardize and simplify workflows using active acoustic processing."
Covaris Adaptive Focused Acoustics® (AFA®) is a proven technology for active extraction of labile, low frequency biomolecules from complex, difficult biological samples. Utilization of Covaris AFA-technology in conjunction with Covaris lysis and purification reagents greatly enhances recovery of nucleic acids from high surface areas, such as CDC-recommended synthetic swab tips, as compared to passive extraction methods (e.g., vortexing etc.). In addition, Covaris has demonstrated equivalent recovery of viral nucleic acids from dry-stabilized whole blood on swabs, as compared to fresh blood.
Covaris is actively supporting customers, organizations, and government agencies in their development of robust and accurate detection assays.